David Michael Nanus, M.D.

Medical Oncology

Publications

Selected from over 150 Publications

Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.Urol Oncology 2010, in press.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Therapy 2010, in press.

Nanus DM and Milowsky MI. Genitourinary Cancers in ASCO-SEP Medical Oncology Self-Evaluation Program Version II, Moore A, ed, American Society of Clinical Oncology 2010, in press.

Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM. A phase I trial of sorafenib plus gemcitabine and           capecitabine for patients with advanced renal cell carcinoma (New York Cancer Consortium trial NCI 6981). Am J Clin Onc 2010;116:1075-83.

Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically-enhanced differential immunocapture (GEDI) and a prostate specific antibody. Lab Chip 2010;10:27-9.

Tagawa ST, Patel-Beltran H, Vallabhajosula S, Goldsmith S, Osborne J, Matulich D, Petrillo K, Parmar S, Selzer J, Nanus DM, Bander NH. Anti-prostate membrane specific antigen-based radioimmunotherapy for prostate cancer. Cancer 2009;116:1075-83.

Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Onc 2009;27:4062-7.

Jeske S, Del Pizzo JJ, Nanus DM. Kidney Cancer in Atlas of Cancer, Markman M, ed,   Lippincott Williams and Wilkins, Philadelphia, 2008.

Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ. A phase II study of estramustine, docetaxel, and exisulind in Patients with hormone- refractory prostate cancer: Results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008;6:110-6.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Rosario C, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM. Phase I/II clinical trial of interferon alpha 2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma J Immunother 2007;30:655-662.

David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy in stage III bladder cancer (1998-2003): A report from the National Cancer Data Base. J Urol 2007;178:451-4.

Nanus DM and Milowsky MI. Genitourinary Cancers in ASCO-SEP Medical Oncology Self-Evaluation Program, Moore A, ed, American Society of Clinical Oncology 2007; 205-238.

Horiguchi A, Zheng R, Goodman OB, Shen R, Guan H, Hersh LB, Nanus DM. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Therapy 2007;14:583-9.

Hussain M, MacVicar GR, Petrylak D, Dunn R, Vaishampayan U, Lara, Jr PN, Chatta G, Nanus DM, Glode LM, Trump D, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced Her-2/neu positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Onc 2007;25:2218-24..

Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. J Urol. 2007;177:911-5

Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-PSMA monoclonal antibody J591 in patients with advanced solid tumor malignancies, J Clin Onc 2007;25:540-7

David KA, Milowsky MI, Nanus DM. Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006;4:263-8.

Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Onc 2005;23:4591-601.

Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551.

Sumitomo M, Iwase A, Navarro D, Zheng R, Kaminetzky D, Shen R, Georgescu M-M, Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004;5:67-78.

Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical utility of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen (PSMA). J Urol 2003;170:S84-S89.

Milowsky MI, Rosmarin AS, Tickoo SK, Papanicolaou NI, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: Case report and review of the literature. Cancer 2002:94;111-116.

Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 1998;4;50-57.

Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-875.

Back to topBack To Top